Regulatory Considerations for Clinical Mass Spectrometry: Multiple Reaction Monitoring

Clinics in Laboratory Medicine

Volumn 31, Issue 3, 2011, Pages 443-453

  Boja, Emily S ^a   Rodriguez, Henry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical proteomics; In vitro diagnostics; Multiple reaction monitoring mass spectrometry; Multiplex; Regulatory science

Indexed keywords

ACCURACY; CLINICAL CHEMISTRY; CLINICAL LABORATORY; DEVICE APPROVAL; DEVICE SAFETY; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HUMAN; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; INSTRUMENT VALIDATION; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; MULTIPLEX PROTEIN ASSAY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN DETERMINATION; PROTEOMICS; RELIABILITY; REVIEW; VALIDATION PROCESS;

CLINICAL CHEMISTRY TESTS; HUMANS; MASS SPECTROMETRY; PRACTICE GUIDELINES AS TOPIC; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052539647     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.07.001     Document Type: Review

References (25)

1. Polanski M., Anderson L. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1:1-48.
2. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
3. Hortin G.L., Carr S.A., Anderson N.L. Introduction: advances in protein analysis for the clinical laboratory. Clin Chem 2009, 56:149-151.
4. García-Foncillas J., Bandrés E., Zárate R., et al. Proteomic analysis in cancer research: potential application in clinical use. Clin Transl Oncol 2006, 8:250-261.
5. Cairns D.A. Statistical issues in quality control of proteomic analyses: Good experimental design and planning. Proteomics 2011, [Epub ahead of print].
6. Paulovich A.G., Whiteaker J.R., Hoofnagle A.N., et al. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008, 2:1386-1402.
7. Regnier F.E., Skates S.J., Mesri M., et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem 2010, 56:165-171.
8. Whiteaker J.R., Zhao L., Anderson L., et al. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010, 9:184-196.
9. Keshishian H., Addona T., Burgess M., et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2009, 8:2339-2349.
10. Anderson N.L., Jackson A., Smith D., et al. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009, 8:995-1005.
11. Zhao M., Nolte D., Cho W., et al. High-speed interferometric detection of label-free immunoassays on the biological compact disc. Clin Chem 2006, 52:2135-2140.
12. Mansfield E., O'Leary T.J., Gutman S.I. Food and Drug Administration regulation of in vitro diagnostic devices. J Mol Diagn 2005, 7:2-7.
13. Boja E.S., Jortani S.A., Ritchie J., et al. The Journal to Regulation of Protein-Based Multiplex Quantitative Assays. Clin Chem 2011, 57:560-567. [Epub ahead of print].
14. Frantz S. An array of problems. Nat Rev. Drug Discov 2005, 4:362-363.
15. Shi L., Tong W., Goodsaid F., et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn 2004, 4:761-777.
16. Michiels S., Koscielny S., Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365:488-492.
17. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol 2006, 24:1151-1161.
18. Patterson T.A., Lobenhofer E.K., Fulmer-Smentek S.B., et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat. Biotechnol 2006, 24:1140-1150.
19. Irizarry R.A., Warren D., Spencer F., et al. Multiple-laboratory comparison of microarray platforms. Nat. Methods 2005, 2:345-350.
20. Strauss E. Arrays of hope. Cell 2006, 127:657-659.
21. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28:827-838.
22. Addona T.A., Abbatiello S.E., Schilling B., et al. A multi-site assessment of precision and reproducibility of multiple reaction monitoring-based measurements by the NCI-CPTAC network: toward quantitative protein biomarker verification in human plasma. Nat Biotechnol 2009, 27:633-641.
23. Ciccimaro E., Hanks S.K., Yu K.H., et al. Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Anal Chem 2009, 81:3304-3313.
24. Russek-Cohen E., Tezak Z., Philip R., et al. Multivariate Assays Reporting a Composite Score. JSM Proceedings CD-Rom 2007.
25. Rodriguez H., Tezak Z., Mesri M., et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA Interagency Oncology Task Force on Molecular Diagnostics. Clin Chem 2010, 56:237-243.